Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses for pan-carcinoma application

K. Takayama, P. N. Reynolds, Y. Adachi, L. Kaliberova, J. Uchino, Yoichi Nakanishi, D. T. Curiel

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Treatment of advanced lung cancer is one of the major challenges in current medicine because of the high morbidity and mortality of the disease. Advanced stage lung cancer is refractory to conventional therapies and has an extremely poor prognosis. Thus, new therapeutic approaches are needed. Lung tumor formation depends on angiogenesis in which the vascular endothelial growth factor (VEGF) produced by cancer cells plays a pivotal role. Neutralizing VEGF with a soluble VEGF receptor suppresses tumor growth; however, the anticancer effect with this therapy is weakened after the intratumoral vascular network is completed. In this study, we turned the expression of VEGF by tumors to therapeutic advantage using a conditionally replication-competent adenovirus (CRAd) in which the expression of E1 is controlled by the human VEGF promoter. This virus achieved good levels of viral replication in lung cancer cells and induced a substantial anticancer effect in vitro and in vivo. As a further enhancement, the cancer cell killing effect was improved with tropism modification of the virus to express the knob domain of Ad3, which improved infectivity for cancer cells. These VEGF promoter-based CRAds also showed a significant cell killing effect for various types of cancer lines other than lung cancer. Conversely, the VEGF promoter has low activity in normal tissues, and the CRAd caused no damage to normal bronchial epithelial cells. Since tumor-associated angiogenesis via VEGF signalling is common in many types of cancers, these CRAds may be applicable to a wide range of tumors. We concluded that VEGF promoter-based CRAds have the potential to be an effective strategy for cancer treatment.

Original languageEnglish
Pages (from-to)105-116
Number of pages12
JournalCancer Gene Therapy
Volume14
Issue number1
DOIs
Publication statusPublished - Jan 22 2007

Fingerprint

Adenoviridae
Vascular Endothelial Growth Factor A
Carcinoma
Neoplasms
Lung Neoplasms
Viruses
Vascular Endothelial Growth Factor Receptor
Tropism
Therapeutics
Blood Vessels
Epithelial Cells
Medicine
Morbidity
Lung
Mortality

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology
  • Cancer Research

Cite this

Takayama, K., Reynolds, P. N., Adachi, Y., Kaliberova, L., Uchino, J., Nakanishi, Y., & Curiel, D. T. (2007). Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses for pan-carcinoma application. Cancer Gene Therapy, 14(1), 105-116. https://doi.org/10.1038/sj.cgt.7700991

Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses for pan-carcinoma application. / Takayama, K.; Reynolds, P. N.; Adachi, Y.; Kaliberova, L.; Uchino, J.; Nakanishi, Yoichi; Curiel, D. T.

In: Cancer Gene Therapy, Vol. 14, No. 1, 22.01.2007, p. 105-116.

Research output: Contribution to journalArticle

Takayama, K, Reynolds, PN, Adachi, Y, Kaliberova, L, Uchino, J, Nakanishi, Y & Curiel, DT 2007, 'Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses for pan-carcinoma application', Cancer Gene Therapy, vol. 14, no. 1, pp. 105-116. https://doi.org/10.1038/sj.cgt.7700991
Takayama, K. ; Reynolds, P. N. ; Adachi, Y. ; Kaliberova, L. ; Uchino, J. ; Nakanishi, Yoichi ; Curiel, D. T. / Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses for pan-carcinoma application. In: Cancer Gene Therapy. 2007 ; Vol. 14, No. 1. pp. 105-116.
@article{fecc8e3c78174f5094e29f13832c2859,
title = "Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses for pan-carcinoma application",
abstract = "Treatment of advanced lung cancer is one of the major challenges in current medicine because of the high morbidity and mortality of the disease. Advanced stage lung cancer is refractory to conventional therapies and has an extremely poor prognosis. Thus, new therapeutic approaches are needed. Lung tumor formation depends on angiogenesis in which the vascular endothelial growth factor (VEGF) produced by cancer cells plays a pivotal role. Neutralizing VEGF with a soluble VEGF receptor suppresses tumor growth; however, the anticancer effect with this therapy is weakened after the intratumoral vascular network is completed. In this study, we turned the expression of VEGF by tumors to therapeutic advantage using a conditionally replication-competent adenovirus (CRAd) in which the expression of E1 is controlled by the human VEGF promoter. This virus achieved good levels of viral replication in lung cancer cells and induced a substantial anticancer effect in vitro and in vivo. As a further enhancement, the cancer cell killing effect was improved with tropism modification of the virus to express the knob domain of Ad3, which improved infectivity for cancer cells. These VEGF promoter-based CRAds also showed a significant cell killing effect for various types of cancer lines other than lung cancer. Conversely, the VEGF promoter has low activity in normal tissues, and the CRAd caused no damage to normal bronchial epithelial cells. Since tumor-associated angiogenesis via VEGF signalling is common in many types of cancers, these CRAds may be applicable to a wide range of tumors. We concluded that VEGF promoter-based CRAds have the potential to be an effective strategy for cancer treatment.",
author = "K. Takayama and Reynolds, {P. N.} and Y. Adachi and L. Kaliberova and J. Uchino and Yoichi Nakanishi and Curiel, {D. T.}",
year = "2007",
month = "1",
day = "22",
doi = "10.1038/sj.cgt.7700991",
language = "English",
volume = "14",
pages = "105--116",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses for pan-carcinoma application

AU - Takayama, K.

AU - Reynolds, P. N.

AU - Adachi, Y.

AU - Kaliberova, L.

AU - Uchino, J.

AU - Nakanishi, Yoichi

AU - Curiel, D. T.

PY - 2007/1/22

Y1 - 2007/1/22

N2 - Treatment of advanced lung cancer is one of the major challenges in current medicine because of the high morbidity and mortality of the disease. Advanced stage lung cancer is refractory to conventional therapies and has an extremely poor prognosis. Thus, new therapeutic approaches are needed. Lung tumor formation depends on angiogenesis in which the vascular endothelial growth factor (VEGF) produced by cancer cells plays a pivotal role. Neutralizing VEGF with a soluble VEGF receptor suppresses tumor growth; however, the anticancer effect with this therapy is weakened after the intratumoral vascular network is completed. In this study, we turned the expression of VEGF by tumors to therapeutic advantage using a conditionally replication-competent adenovirus (CRAd) in which the expression of E1 is controlled by the human VEGF promoter. This virus achieved good levels of viral replication in lung cancer cells and induced a substantial anticancer effect in vitro and in vivo. As a further enhancement, the cancer cell killing effect was improved with tropism modification of the virus to express the knob domain of Ad3, which improved infectivity for cancer cells. These VEGF promoter-based CRAds also showed a significant cell killing effect for various types of cancer lines other than lung cancer. Conversely, the VEGF promoter has low activity in normal tissues, and the CRAd caused no damage to normal bronchial epithelial cells. Since tumor-associated angiogenesis via VEGF signalling is common in many types of cancers, these CRAds may be applicable to a wide range of tumors. We concluded that VEGF promoter-based CRAds have the potential to be an effective strategy for cancer treatment.

AB - Treatment of advanced lung cancer is one of the major challenges in current medicine because of the high morbidity and mortality of the disease. Advanced stage lung cancer is refractory to conventional therapies and has an extremely poor prognosis. Thus, new therapeutic approaches are needed. Lung tumor formation depends on angiogenesis in which the vascular endothelial growth factor (VEGF) produced by cancer cells plays a pivotal role. Neutralizing VEGF with a soluble VEGF receptor suppresses tumor growth; however, the anticancer effect with this therapy is weakened after the intratumoral vascular network is completed. In this study, we turned the expression of VEGF by tumors to therapeutic advantage using a conditionally replication-competent adenovirus (CRAd) in which the expression of E1 is controlled by the human VEGF promoter. This virus achieved good levels of viral replication in lung cancer cells and induced a substantial anticancer effect in vitro and in vivo. As a further enhancement, the cancer cell killing effect was improved with tropism modification of the virus to express the knob domain of Ad3, which improved infectivity for cancer cells. These VEGF promoter-based CRAds also showed a significant cell killing effect for various types of cancer lines other than lung cancer. Conversely, the VEGF promoter has low activity in normal tissues, and the CRAd caused no damage to normal bronchial epithelial cells. Since tumor-associated angiogenesis via VEGF signalling is common in many types of cancers, these CRAds may be applicable to a wide range of tumors. We concluded that VEGF promoter-based CRAds have the potential to be an effective strategy for cancer treatment.

UR - http://www.scopus.com/inward/record.url?scp=33845640114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845640114&partnerID=8YFLogxK

U2 - 10.1038/sj.cgt.7700991

DO - 10.1038/sj.cgt.7700991

M3 - Article

C2 - 17024232

AN - SCOPUS:33845640114

VL - 14

SP - 105

EP - 116

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 1

ER -